HRP20211682T1 - 2-(2,4,5-supstituirani-anilino) pirimidinski spojevi - Google Patents
2-(2,4,5-supstituirani-anilino) pirimidinski spojevi Download PDFInfo
- Publication number
- HRP20211682T1 HRP20211682T1 HRP20211682TT HRP20211682T HRP20211682T1 HR P20211682 T1 HRP20211682 T1 HR P20211682T1 HR P20211682T T HRP20211682T T HR P20211682TT HR P20211682 T HRP20211682 T HR P20211682T HR P20211682 T1 HRP20211682 T1 HR P20211682T1
- Authority
- HR
- Croatia
- Prior art keywords
- theta
- diffraction pattern
- dimethylaminoethylmethylamino
- methylindol
- pyrimidin
- Prior art date
Links
- 229910016523 CuKa Inorganic materials 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 230000005855 radiation Effects 0.000 claims 6
- FUKSNUHSJBTCFJ-UHFFFAOYSA-N osimertinib mesylate Chemical compound CS(O)(=O)=O.COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 FUKSNUHSJBTCFJ-UHFFFAOYSA-N 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 125000005610 enamide group Chemical group 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
- Luminescent Compositions (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512061P | 2011-07-27 | 2011-07-27 | |
| US201261591363P | 2012-01-27 | 2012-01-27 | |
| EP20157927.3A EP3686194B1 (en) | 2011-07-27 | 2012-07-25 | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211682T1 true HRP20211682T1 (hr) | 2022-03-04 |
Family
ID=46875901
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211682TT HRP20211682T1 (hr) | 2011-07-27 | 2012-07-25 | 2-(2,4,5-supstituirani-anilino) pirimidinski spojevi |
| HRP20160135TT HRP20160135T1 (hr) | 2011-07-27 | 2012-07-25 | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka |
| HRP20171957TT HRP20171957T1 (hr) | 2011-07-27 | 2017-12-18 | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka |
| HRP20200624TT HRP20200624T1 (hr) | 2011-07-27 | 2020-04-20 | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160135TT HRP20160135T1 (hr) | 2011-07-27 | 2012-07-25 | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka |
| HRP20171957TT HRP20171957T1 (hr) | 2011-07-27 | 2017-12-18 | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka |
| HRP20200624TT HRP20200624T1 (hr) | 2011-07-27 | 2020-04-20 | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka |
Country Status (38)
Families Citing this family (223)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| ES2645689T5 (en) | 2008-05-21 | 2025-06-24 | Takeda Pharmaceuticals Co | Phosphorous derivatives as kinase inhibitors |
| MX2011003015A (es) | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| US9200007B2 (en) | 2009-08-20 | 2015-12-01 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| KR101884010B1 (ko) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
| JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| PT2951183T (pt) | 2013-01-29 | 2019-06-17 | Aptinyx Inc | Moduladores espirolactamas de um recetor nmda e as suas utilizações |
| PE20151427A1 (es) * | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| WO2014144847A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2014210354A1 (en) * | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| CN104292142B (zh) * | 2013-07-17 | 2019-05-14 | 天津大地康和医药技术有限公司 | 一种n-芳基杂环丁烷脱芳基方法 |
| US9550770B2 (en) | 2013-08-23 | 2017-01-24 | Neupharma, Inc. | Substituted quinazolines for inhibiting kinase activity |
| CN105939998B (zh) * | 2013-10-21 | 2019-04-16 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| MX369111B (es) * | 2014-04-04 | 2019-10-29 | Astrazeneca Ab | Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. |
| US20170166598A1 (en) * | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN111875585B (zh) * | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
| JP6230205B2 (ja) * | 2014-06-19 | 2017-11-15 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| CN105254615B (zh) * | 2014-07-11 | 2017-02-22 | 杭州华东医药集团新药研究院有限公司 | 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途 |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| CN104140418B (zh) * | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途 |
| CN106458969A (zh) * | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| CN104356040A (zh) * | 2014-09-17 | 2015-02-18 | 爱斯特（成都）生物制药有限公司 | 一种1-二苯甲基-3-羟基氮杂环丁烷盐酸盐的制备方法 |
| CN105461695B (zh) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN105524068B (zh) * | 2014-09-30 | 2017-11-24 | 上海海雁医药科技有限公司 | 氮杂双环衍生物、其制法与医药上的用途 |
| CN105237515B (zh) * | 2014-10-10 | 2018-06-05 | 益方生物科技（上海）有限公司 | 氘代嘧啶类化合物、其制备方法、药物组合物和用途 |
| CN111170999B (zh) * | 2014-10-11 | 2023-06-30 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| RS66529B1 (sr) * | 2014-10-13 | 2025-03-31 | Yuhan Corp | Jedinjenja i kompozicije za modulaciju aktivnosti egfr mutant kinaze |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| CN114224894B (zh) * | 2014-12-03 | 2025-01-07 | 奥克兰联合服务有限公司 | 用于治疗癌症的激酶抑制剂前药 |
| MX382869B (es) * | 2014-12-11 | 2025-03-13 | Beta Pharma Inc | Derivados de 2-anilinopirimidina sustituida como moduladores de egfr. |
| WO2016105525A2 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| CN104961731A (zh) * | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 |
| WO2016133935A1 (en) | 2015-02-17 | 2016-08-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| TWI687420B (zh) * | 2015-04-29 | 2020-03-11 | 大陸商南京聖和藥業股份有限公司 | 稠環或三環芳基嘧啶化合物用作激酶抑制劑 |
| CN107614503B (zh) | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
| CN104817541B (zh) * | 2015-05-11 | 2017-06-16 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的合成方法 |
| HK1251567A1 (zh) * | 2015-05-13 | 2019-02-01 | Ariad Pharmaceuticals, Inc. | 用於激酶抑制的杂芳基化合物 |
| CN108012529A (zh) | 2015-05-15 | 2018-05-08 | 诺华股份有限公司 | 治疗egfr突变的癌症的方法 |
| CN104910049B (zh) * | 2015-06-16 | 2016-06-29 | 苏州明锐医药科技有限公司 | Azd9291中间体及其制备方法 |
| RU2734849C2 (ru) * | 2015-07-16 | 2020-10-23 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Производные анилинпиримидина и их применения |
| US10550112B2 (en) | 2015-07-20 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Pyrimidines as EGFR inhibitors and methods of treating disorders |
| US10561646B2 (en) | 2015-07-24 | 2020-02-18 | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. | EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof |
| CN105001208A (zh) * | 2015-08-06 | 2015-10-28 | 南京雷科星生物技术有限公司 | 一种表皮生长因子受体egfr抑制剂及其制备方法与用途 |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| AU2015407300B2 (en) * | 2015-08-31 | 2019-06-20 | Wuxi Shuangliang Biotechnology Co., Ltd. | 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof |
| CN106117185B (zh) * | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
| CN106478605A (zh) * | 2015-09-02 | 2017-03-08 | 上海页岩科技有限公司 | 嘧啶类化合物、其制备方法和医药用途 |
| RU2603960C1 (ru) * | 2015-11-19 | 2016-12-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака |
| RU2606949C9 (ru) * | 2015-11-19 | 2018-03-14 | ЗАО "Р-Фарм" | Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака |
| CN106749267B (zh) * | 2015-11-23 | 2020-08-21 | 南京圣和药业股份有限公司 | 新的表皮生长因子受体抑制剂及其应用 |
| CN106810553B (zh) * | 2015-11-30 | 2020-03-17 | 江苏正大丰海制药有限公司 | 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 |
| AU2016362394B2 (en) * | 2015-12-03 | 2021-01-14 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Heterocycle compounds and uses thereof |
| CN108289895B (zh) * | 2015-12-03 | 2021-07-20 | 浙江尖峰亦恩生物科技有限公司 | 噻吩并嘧啶衍生物及其用途 |
| CN105601620A (zh) * | 2015-12-25 | 2016-05-25 | 北京康立生医药技术开发有限公司 | 一种甲磺酸迈瑞替尼的制备方法 |
| CN106928150B (zh) | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| WO2017120429A1 (en) | 2016-01-07 | 2017-07-13 | CS Pharmasciences, Inc. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| CN105646454B (zh) * | 2016-01-19 | 2018-05-08 | 浙江大学 | 含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用 |
| CN106995437A (zh) * | 2016-01-22 | 2017-08-01 | 齐鲁制药有限公司 | 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途 |
| CN106995435B (zh) * | 2016-01-22 | 2018-06-08 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
| TWI745345B (zh) * | 2016-02-01 | 2021-11-11 | 瑞典商阿斯特捷利康公司 | 製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法 |
| CN107043368B (zh) * | 2016-02-05 | 2020-07-31 | 齐鲁制药有限公司 | 芳胺嘧啶化合物及其盐的结晶 |
| CN107043369A (zh) * | 2016-02-06 | 2017-08-15 | 焦玉奇 | 2‑(2,4,5‑取代苯胺)嘧啶衍生物 |
| CN107098887B (zh) * | 2016-02-22 | 2019-08-09 | 复旦大学 | 嘧啶类化合物 |
| CN105777716B (zh) * | 2016-02-25 | 2018-04-10 | 清华大学 | 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
| CN105646467B (zh) * | 2016-02-25 | 2018-07-20 | 黄燕鸽 | 一种抗癌化合物奥美替尼及其合成方法 |
| CN105585557B (zh) * | 2016-02-25 | 2018-06-22 | 清华大学 | 用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
| CN107163027B (zh) * | 2016-03-07 | 2019-11-05 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
| CN107163026B (zh) * | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
| CN107188888A (zh) * | 2016-03-15 | 2017-09-22 | 罗欣生物科技（上海）有限公司 | 一种制备甲磺酸迈瑞替尼的方法 |
| CN112645933B (zh) * | 2016-03-22 | 2022-02-11 | 江苏豪森药业集团有限公司 | Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用 |
| CN109715164A (zh) | 2016-05-11 | 2019-05-03 | 贝达医药公司 | 作为用于治疗脑癌之治疗剂的2-苯胺基嘧啶衍生物 |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017267708B2 (en) | 2016-05-19 | 2020-02-20 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| CA3027732A1 (en) | 2016-06-17 | 2017-12-21 | Beta Pharma, Inc. | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
| CN107522690B (zh) * | 2016-06-20 | 2022-08-05 | 海南先声药业有限公司 | 一种Osimertinib的制备方法 |
| CN107540661A (zh) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
| CN107663207B (zh) * | 2016-07-27 | 2021-07-30 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法 |
| CN107663208B (zh) * | 2016-07-27 | 2021-10-15 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途 |
| MX388786B (es) | 2016-08-01 | 2025-03-20 | Aptinyx Inc | Moduladores nmda espiro-lactam y métodos de uso de los mismos. |
| CA3031539C (en) | 2016-08-01 | 2023-11-28 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN109661398B (zh) | 2016-08-01 | 2022-07-05 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途 |
| CN109906218B (zh) | 2016-08-01 | 2023-01-17 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| EP4006035B1 (en) | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| CN106366072B (zh) * | 2016-08-19 | 2018-12-07 | 上海工程技术大学 | 一种azd9291的制备方法 |
| CN106366022B (zh) * | 2016-08-19 | 2018-03-13 | 上海工程技术大学 | 一种用于制备azd9291的中间体及其制备方法和应用 |
| CN106397407B (zh) * | 2016-08-31 | 2018-09-04 | 浙江科聚化工有限公司 | 抗肿瘤药物azd9291衍生物的制备方法 |
| CN106432231B (zh) * | 2016-09-09 | 2018-06-12 | 无锡佰翱得生物科学有限公司 | Azd9291的药用盐、及其晶型和制备方法 |
| JP6746794B2 (ja) * | 2016-09-19 | 2020-08-26 | 南京創特医薬科技有限公司Ｎａｎｊｉｎｇ Ｃｈｕａｎｇｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ | 重水素化３−（４，５−置換アミノピリミジン）フェニル誘導体及びその使用 |
| CN107955019B (zh) * | 2016-10-17 | 2021-09-14 | 广东众生药业股份有限公司 | 一种egfr抑制剂的盐型、晶型及其制备方法 |
| WO2018073839A1 (en) | 2016-10-18 | 2018-04-26 | Mylan Laboratories Limited | Amorphous osimertinib mesylate, processes for its preparation and solid amorphous dispersions thereof |
| CA3040348A1 (en) * | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
| CN106496196B (zh) * | 2016-10-20 | 2019-07-02 | 南京雷科星生物技术有限公司 | 一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途 |
| CN106543060B (zh) * | 2016-10-31 | 2018-11-06 | 湖南欧亚药业有限公司 | 一种奥斯替尼甲磺酸盐的制备方法 |
| CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
| AR110778A1 (es) | 2017-01-26 | 2019-05-02 | Hanmi Pharm Ind Co Ltd | Compuestos de pirimidina y su uso farmacéutico |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| CN110325191A (zh) * | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| TWI796326B (zh) | 2017-03-24 | 2023-03-21 | 日商第一三共股份有限公司 | 含有ａｘｌ抑制劑與ｅｇｆｒ酪胺酸激酶抑制藥的醫藥品及其用途 |
| CN106883216B (zh) * | 2017-04-06 | 2020-03-13 | 张家港威胜生物医药有限公司 | 一种奥希替尼的制备方法 |
| CN108503627A (zh) * | 2017-04-19 | 2018-09-07 | 郑州泰基鸿诺医药股份有限公司 | 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| CN106967050A (zh) * | 2017-05-11 | 2017-07-21 | 北京工业大学 | 一种azd9291的制备方法 |
| CN108929311B (zh) * | 2017-05-22 | 2020-07-28 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
| US10882845B2 (en) | 2017-05-24 | 2021-01-05 | TYK Medicines Inc. | Crystal form of deuterated AZD9291, preparation method therefor, and use thereof |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| ES2963921T3 (es) * | 2017-06-13 | 2024-04-03 | Beijing Avlstone Biotechnology Co Ltd | Compuestos de aminopirimidina, su método de preparación y uso de los mismos |
| TW201904577A (zh) | 2017-06-16 | 2019-02-01 | 美商貝達醫藥公司 | N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物 |
| CN108467385A (zh) * | 2017-06-27 | 2018-08-31 | 浙江同源康医药股份有限公司 | 一种氘代奥斯替尼衍生物及其应用 |
| CN107095873A (zh) * | 2017-06-28 | 2017-08-29 | 卢凯华 | 具有低耐药性的抗肺癌靶向药物组合物 |
| CN107216313B (zh) * | 2017-06-29 | 2019-11-19 | 山东四环药业股份有限公司 | 一种抗肿瘤药物azd9291的制备方法 |
| WO2019010619A1 (zh) * | 2017-07-10 | 2019-01-17 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
| RS64545B1 (sr) | 2017-07-28 | 2023-09-29 | Yuhan Corp | Postupak za pripremu n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida |
| MY198379A (en) * | 2017-07-28 | 2023-08-28 | Yuhan Corp | Improved Process for Preparing Aminopyrimidine Derivatives |
| CN107266426A (zh) * | 2017-08-15 | 2017-10-20 | 南通因诺威医药科技有限公司 | 2‑氨烃基嘧啶类化合物及其制备方法和用途 |
| WO2019040348A1 (en) | 2017-08-21 | 2019-02-28 | Eli Lilly And Company | COMBINATIONS OF EGFR INHIBITORS AND ANTI-VEGFR -2 HUMAN ANTIBODIES |
| CN109485638B (zh) * | 2017-09-12 | 2020-07-17 | 新发药业有限公司 | 一种奥希替尼中间体的制备方法 |
| CN107915725B (zh) * | 2017-10-20 | 2023-06-27 | 复旦大学 | Azd9291的药用盐及其制备方法 |
| IL274663B2 (en) * | 2017-11-17 | 2024-01-01 | Univ Illinois | Cancer therapy by degrading dual mek signaling |
| JP2021509680A (ja) | 2018-01-08 | 2021-04-01 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｇ１ｔ３８の優れた投与レジメン |
| CN112204031B (zh) | 2018-01-31 | 2024-05-24 | 元羿生物科技(香港)有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP7550646B2 (ja) | 2018-02-08 | 2024-09-13 | ニューファーマ，インク． | 特定の化学物質、組成物、および方法 |
| US20200368231A1 (en) | 2018-02-12 | 2020-11-26 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| WO2019164949A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |
| EP3755330A4 (en) * | 2018-02-20 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND THEIR METHODS OF USE |
| CN108250187B (zh) * | 2018-03-01 | 2021-01-05 | 中国科学院上海药物研究所 | 吲哚-1-碳酸酯类化合物、其制备方法和应用 |
| CN108191861B (zh) * | 2018-03-01 | 2020-10-02 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺 |
| WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
| CN108218839A (zh) * | 2018-03-20 | 2018-06-29 | 上药康丽（常州）药业有限公司 | 一种抗肿瘤药物azd9291的制备方法 |
| CN109666024A (zh) * | 2018-03-20 | 2019-04-23 | 兰州大学 | 2-氧嘧啶类化合物及其制备方法和用途 |
| CN108484579A (zh) * | 2018-03-28 | 2018-09-04 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成奥希替尼中间体的方法 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| CA3099737A1 (en) | 2018-05-14 | 2019-11-21 | Ariad Pharmaceuticals, Inc. | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
| US11639344B2 (en) | 2018-05-15 | 2023-05-02 | InventisBio Co., Ltd. | EGFR inhibitors |
| CN110606842B (zh) * | 2018-06-15 | 2021-06-01 | 上海艾力斯医药科技股份有限公司 | 吡啶胺基嘧啶衍生物的制备方法及其中间体 |
| CN110698461B (zh) * | 2018-07-09 | 2024-04-05 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制备方法 |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CN113329749B (zh) | 2018-10-05 | 2025-02-11 | 伊利诺伊大学董事会 | 用于治疗葡萄膜黑色素瘤的联合疗法 |
| CN109134435B (zh) * | 2018-10-29 | 2023-01-03 | 湖南大学 | 一种奥希替尼azd9291的合成方法 |
| CN111233774B (zh) * | 2018-11-28 | 2023-04-14 | 鲁南制药集团股份有限公司 | 一种胺基嘧啶类化合物 |
| CA3124330A1 (en) | 2018-12-21 | 2020-06-25 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN113227073B (zh) * | 2019-01-05 | 2022-09-16 | 山东轩竹医药科技有限公司 | Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型 |
| CN111410651B (zh) * | 2019-01-05 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂的盐及其晶型 |
| WO2020171646A1 (ko) | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| CN113773304B (zh) * | 2019-02-25 | 2023-03-10 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
| CN111606889B (zh) * | 2019-02-25 | 2023-03-07 | 上海翰森生物医药科技有限公司 | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 |
| CN109928956B (zh) * | 2019-02-27 | 2020-10-13 | 杭州偶联医药科技有限公司 | 一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用 |
| WO2020192302A1 (zh) * | 2019-03-27 | 2020-10-01 | 广州必贝特医药技术有限公司 | 含嘧啶的三取代咪唑类化合物及其应用 |
| EP3946346A1 (en) | 2019-03-29 | 2022-02-09 | Astrazeneca AB | Osimertinib for use in the treatment of non-small cell lung cancer |
| CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
| EA202100252A1 (ru) * | 2019-04-09 | 2022-03-10 | Хэнань Дженьюин Биотек Ко., Лтд. | Производная 2-(2,4,5-замещенного фениламино)пиримидина и его кристаллическая форма "в" |
| CN109942550A (zh) * | 2019-04-15 | 2019-06-28 | 广州医科大学附属第一医院（广州呼吸中心） | 11c标记的egfr正电子示踪剂及其制备方法和应用 |
| JP7534795B2 (ja) | 2019-05-01 | 2024-08-15 | クレキシオ バイオサイエンシーズ エルティーディー． | そう痒症を治療する方法 |
| TWI875756B (zh) | 2019-05-05 | 2025-03-11 | 美商基尼特奇公司 | Ｃｄｋ抑制劑 |
| AU2020277541A1 (en) * | 2019-05-22 | 2022-01-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Indole derivative-containing inhibitor, preparation method therefor and application thereof |
| JP2022538817A (ja) | 2019-06-27 | 2022-09-06 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｆｌｔ３阻害剤および化学療法剤を含む急性骨髄白血病を治療するための薬学的組成物 |
| CN110283162B (zh) * | 2019-07-09 | 2022-04-05 | 辽宁大学 | 一种表皮生长因子受体抑制剂及其应用 |
| CN110483486B (zh) * | 2019-09-17 | 2024-01-26 | 鲁南制药集团股份有限公司 | 一种奥西替尼酮咯酸盐晶型及其制备方法 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2021111462A1 (en) * | 2019-12-02 | 2021-06-10 | Natco Pharma Limited | An improved process for the preparation of osimertinib mesylate |
| WO2021127404A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| IL272441B (en) * | 2020-02-03 | 2021-08-31 | Ottek Ltd | System and method for driving an endoscope |
| CN113372331B (zh) * | 2020-03-10 | 2023-09-12 | 鲁南制药集团股份有限公司 | 一种奥希替尼一水合物新晶型 |
| CN113372332B (zh) * | 2020-03-10 | 2023-09-12 | 鲁南制药集团股份有限公司 | 一种奥希替尼新晶型 |
| CN111303123B (zh) * | 2020-03-31 | 2021-08-31 | 南京雷正医药科技有限公司 | 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用 |
| CN111285852A (zh) * | 2020-04-02 | 2020-06-16 | 广州博济医药生物技术股份有限公司 | 氘代奥希替尼药用盐的晶型及其制备方法 |
| CN111303124A (zh) * | 2020-04-08 | 2020-06-19 | 北京赛思源生物医药技术有限公司 | 一种甲磺酸奥希替尼的新晶体 |
| US20210369709A1 (en) * | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN113801101A (zh) * | 2020-06-15 | 2021-12-17 | 鲁南制药集团股份有限公司 | Azd9291-2-酮戊二酸盐及其制备方法 |
| CN113929663B (zh) * | 2020-06-29 | 2025-06-17 | 鲁南制药集团股份有限公司 | Azd9291-2-吲哚甲酸盐及其制备方法 |
| CN113929664A (zh) * | 2020-07-13 | 2022-01-14 | 鲁南制药集团股份有限公司 | Azd9291-3,5-吡啶二羧酸盐及其制备方法 |
| CN113968845A (zh) * | 2020-07-24 | 2022-01-25 | 鲁南制药集团股份有限公司 | Azd9291-没食子酸盐及其制备方法 |
| US20230321098A1 (en) | 2020-08-25 | 2023-10-12 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
| IL301524A (en) | 2020-09-23 | 2023-05-01 | Erasca Inc | Tricyclic pyridones and pyrimidones |
| CN112430231B (zh) * | 2020-11-06 | 2022-09-30 | 德州德药制药有限公司 | 一种azd9291的工业化制备方法 |
| CN112358468B (zh) * | 2020-11-10 | 2022-03-22 | 德州德药制药有限公司 | 一种工业化合成azd9291的方法 |
| CN116018141B (zh) * | 2020-11-19 | 2025-02-28 | 上海翰森生物医药科技有限公司 | 一种含吲哚类衍生物的盐、晶型及其制备方法和应用 |
| US11780824B2 (en) * | 2020-12-16 | 2023-10-10 | Scinopharm Taiwan, Ltd. | Process for preparing osimertinib or a salt thereof |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| EP4355330A1 (en) | 2021-06-15 | 2024-04-24 | Genentech, Inc. | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer |
| CN113387935B (zh) * | 2021-07-23 | 2022-06-10 | 苏州雅深智慧科技有限公司 | 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途 |
| CN117440945A (zh) * | 2021-08-06 | 2024-01-23 | 上海和誉生物医药科技有限公司 | 嘧啶或吡啶衍生物及其制备方法和在药学上的应用 |
| KR20240055046A (ko) | 2021-09-02 | 2024-04-26 | 신톤 비.브이. | 오시머티닙을 제조하는 방법 |
| CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
| JP7702205B2 (ja) * | 2021-09-15 | 2025-07-03 | 株式会社東芝 | 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去 |
| CN116099006A (zh) * | 2021-11-10 | 2023-05-12 | 上海交通大学医学院附属新华医院 | 奥西替尼及其药学上可接受的盐在制备急性髓细胞白血病药物中的应用 |
| CN114014847B (zh) * | 2021-12-08 | 2023-11-03 | 滨州医学院 | 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| CN119278041A (zh) | 2022-03-31 | 2025-01-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂 |
| AR128999A1 (es) | 2022-04-07 | 2024-07-03 | Astrazeneca Ab | Proceso mejorado para la fabricación de osimertinib |
| US20250214995A1 (en) | 2022-04-28 | 2025-07-03 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| KR20250016160A (ko) * | 2022-05-03 | 2025-02-03 | 도이체스 첸트룸 퓌어 노이로데게네라티페 에르크랑쿵겐 이. 브이. | 타우 단백질 억제제 |
| AU2023300198A1 (en) | 2022-06-27 | 2025-02-13 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| CN115650974B (zh) * | 2022-08-04 | 2024-06-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用 |
| EP4590662A1 (en) * | 2022-09-19 | 2025-07-30 | Advenchen Pharmaceuticals, LLC | Novel pyrimidine compound as kinase inhibitors with biological activities on egfr mutants |
| CN116655601B (zh) * | 2023-06-05 | 2025-08-29 | 河南应用技术职业学院 | 一种奥希替尼的合成方法 |
| WO2025124936A1 (en) | 2023-12-15 | 2025-06-19 | Synthon B.V. | A process for making osimertinib |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
| WO2026009146A1 (en) | 2024-07-01 | 2026-01-08 | Hetero Labs Limited | Benzimidazole compounds as egfr inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288138B6 (sk) | 1999-02-10 | 2013-11-04 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| US6881737B2 (en) * | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| EP1828185B1 (en) * | 2004-12-21 | 2009-05-06 | SmithKline Beecham Corporation | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| AU2006210572B2 (en) | 2005-02-03 | 2011-08-04 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| RU2008122070A (ru) | 2005-11-03 | 2009-12-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Аминопиридины, используемые в качестве ингибиторов киназ |
| GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| ES2421450T3 (es) * | 2005-12-05 | 2013-09-02 | Glaxosmithkline Llc | 2-Pirimidinil-pirazolopiridinas inhibidoras de la quinasa ErbB |
| WO2007149427A2 (en) | 2006-06-22 | 2007-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2657260A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| AU2008314632B2 (en) | 2007-10-19 | 2015-05-28 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI546290B (zh) * | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| RU2014150660A (ru) | 2008-09-05 | 2015-07-20 | Селджен Авиломикс Рисерч, Инк. | Алгоритм разработки необратимо действующих ингибиторов |
| US20110183975A1 (en) | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
| KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| IN2012DN02534A (enExample) | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
| WO2011053476A1 (en) * | 2009-11-02 | 2011-05-05 | Abbott Laboratories | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| WO2011140338A1 (en) | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| USRE46511E1 (en) | 2010-06-23 | 2017-08-15 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| TW201219383A (en) | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
| KR101884010B1 (ko) * | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
| JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
-
2012
- 2012-07-25 JP JP2013541431A patent/JP5427321B2/ja active Active
- 2012-07-25 DK DK20157798.8T patent/DK3686193T3/da active
- 2012-07-25 MY MYPI2013702541A patent/MY161925A/en unknown
- 2012-07-25 RS RS20200459A patent/RS60190B1/sr unknown
- 2012-07-25 RS RS20160094A patent/RS54653B1/sr unknown
- 2012-07-25 SI SI201230455T patent/SI2736895T1/sl unknown
- 2012-07-25 PL PL12759801T patent/PL2736895T3/pl unknown
- 2012-07-25 BR BR122014026094-6A patent/BR122014026094B1/pt active IP Right Grant
- 2012-07-25 HU HUE12759801A patent/HUE026429T2/en unknown
- 2012-07-25 EA EA201792394A patent/EA033733B1/ru unknown
- 2012-07-25 EP EP22189028.8A patent/EP4119551A1/en active Pending
- 2012-07-25 PL PL17194307T patent/PL3333161T3/pl unknown
- 2012-07-25 HU HUE20157927A patent/HUE056365T2/hu unknown
- 2012-07-25 RS RS20171309A patent/RS56679B1/sr unknown
- 2012-07-25 WO PCT/GB2012/051783 patent/WO2013014448A1/en not_active Ceased
- 2012-07-25 LT LTEP17194307.9T patent/LT3333161T/lt unknown
- 2012-07-25 CA CA2881991A patent/CA2881991C/en active Active
- 2012-07-25 SG SG10201910986QA patent/SG10201910986QA/en unknown
- 2012-07-25 SI SI201231167T patent/SI3009431T1/en unknown
- 2012-07-25 CA CA2882018A patent/CA2882018C/en active Active
- 2012-07-25 ME MEP-2017-290A patent/ME02887B/me unknown
- 2012-07-25 CN CN201410287447.1A patent/CN104109151B/zh active Active
- 2012-07-25 DK DK15192658.1T patent/DK3009431T3/en active
- 2012-07-25 CN CN201510641921.0A patent/CN105198862B/zh active Active
- 2012-07-25 CA CA2881987A patent/CA2881987C/en active Active
- 2012-07-25 KR KR1020147011325A patent/KR101691268B1/ko active Active
- 2012-07-25 ES ES15192658.1T patent/ES2654177T3/es active Active
- 2012-07-25 SG SG10201402857QA patent/SG10201402857QA/en unknown
- 2012-07-25 SM SM20210652T patent/SMT202100652T1/it unknown
- 2012-07-25 BR BR122014026150-0A patent/BR122014026150B1/pt active IP Right Grant
- 2012-07-25 DK DK12759801.9T patent/DK2736895T3/da active
- 2012-07-25 PL PL20157798T patent/PL3686193T3/pl unknown
- 2012-07-25 HU HUE15192658A patent/HUE037645T2/hu unknown
- 2012-07-25 CN CN201510639096.0A patent/CN105348266B/zh active Active
- 2012-07-25 EA EA201690328A patent/EA029488B1/ru not_active IP Right Cessation
- 2012-07-25 CN CN201510639051.3A patent/CN105254616B/zh active Active
- 2012-07-25 LT LTEP15192658.1T patent/LT3009431T/lt unknown
- 2012-07-25 PT PT201579273T patent/PT3686194T/pt unknown
- 2012-07-25 CA CA2881993A patent/CA2881993C/en active Active
- 2012-07-25 PT PT201577988T patent/PT3686193T/pt unknown
- 2012-07-25 SI SI201231963T patent/SI3686194T1/sl unknown
- 2012-07-25 PL PL15192658T patent/PL3009431T3/pl unknown
- 2012-07-25 HU HUE17194307A patent/HUE049060T2/hu unknown
- 2012-07-25 MY MYPI2019007672A patent/MY194532A/en unknown
- 2012-07-25 EA EA201391491A patent/EA024421B1/ru active Protection Beyond IP Right Term
- 2012-07-25 CN CN201510507888.2A patent/CN105175396B/zh active Active
- 2012-07-25 KR KR1020137003097A patent/KR101410902B1/ko active Active
- 2012-07-25 CA CA2843109A patent/CA2843109C/en active Active
- 2012-07-25 SI SI201231771T patent/SI3333161T1/sl unknown
- 2012-07-25 ES ES20157927T patent/ES2900230T3/es active Active
- 2012-07-25 US US13/557,871 patent/US8946235B2/en active Active
- 2012-07-25 KR KR1020147008572A patent/KR101422619B1/ko active Active
- 2012-07-25 LT LTEP20157927.3T patent/LT3686194T/lt unknown
- 2012-07-25 DK DK20157927.3T patent/DK3686194T3/da active
- 2012-07-25 ME MEP-2020-87A patent/ME03785B/me unknown
- 2012-07-25 MX MX2014000528A patent/MX2014000528A/es unknown
- 2012-07-25 BR BR122014026114-4A patent/BR122014026114B1/pt active IP Right Grant
- 2012-07-25 EP EP15192658.1A patent/EP3009431B1/en active Active
- 2012-07-25 SG SG2013081716A patent/SG194783A1/en unknown
- 2012-07-25 PE PE2013002532A patent/PE20141700A1/es active IP Right Grant
- 2012-07-25 PT PT151926581T patent/PT3009431T/pt unknown
- 2012-07-25 EP EP20157927.3A patent/EP3686194B1/en active Active
- 2012-07-25 BR BR112014001768-9A patent/BR112014001768B1/pt active IP Right Grant
- 2012-07-25 ES ES12759801.9T patent/ES2564671T3/es active Active
- 2012-07-25 PL PL20157927T patent/PL3686194T3/pl unknown
- 2012-07-25 EP EP22158770.2A patent/EP4086246A1/en not_active Withdrawn
- 2012-07-25 EP EP12759801.9A patent/EP2736895B1/en active Active
- 2012-07-25 SG SG10201402860QA patent/SG10201402860QA/en unknown
- 2012-07-25 HR HRP20211682TT patent/HRP20211682T1/hr unknown
- 2012-07-25 EP EP17194307.9A patent/EP3333161B1/en active Active
- 2012-07-25 SM SM20200208T patent/SMT202000208T1/it unknown
- 2012-07-25 PH PH1/2013/502312A patent/PH12013502312A1/en unknown
- 2012-07-25 DK DK17194307.9T patent/DK3333161T3/da active
- 2012-07-25 CN CN201410287156.2A patent/CN104109161B/zh active Active
- 2012-07-25 ES ES20157798T patent/ES2914854T3/es active Active
- 2012-07-25 RS RS20211378A patent/RS62542B1/sr unknown
- 2012-07-25 PT PT171943079T patent/PT3333161T/pt unknown
- 2012-07-25 ES ES17194307T patent/ES2791308T3/es active Active
- 2012-07-25 EP EP20157798.8A patent/EP3686193B1/en active Active
- 2012-07-25 AU AU2012288626A patent/AU2012288626C1/en active Active
- 2012-07-25 ME MEP-2016-34A patent/ME02382B/me unknown
- 2012-07-25 MX MX2015017622A patent/MX377900B/es unknown
- 2012-07-25 HR HRP20160135TT patent/HRP20160135T1/hr unknown
- 2012-07-25 CN CN201280033773.9A patent/CN103702990B/zh active Active
- 2012-07-25 SG SG10201910984XA patent/SG10201910984XA/en unknown
- 2012-07-26 AR ARP120102716 patent/AR087336A1/es active IP Right Grant
- 2012-07-26 TW TW101127018A patent/TWI465445B/zh active
- 2012-07-26 TW TW103124452A patent/TWI555743B/zh active
- 2012-07-26 TW TW105130486A patent/TWI583386B/zh active
- 2012-07-26 UY UY34219A patent/UY34219A/es not_active Application Discontinuation
-
2013
- 2013-06-05 JP JP2013118744A patent/JP5537704B2/ja active Active
- 2013-10-31 IL IL229199A patent/IL229199A/en active IP Right Grant
- 2013-11-13 DO DO2013000263A patent/DOP2013000263A/es unknown
- 2013-11-14 CL CL2013003281A patent/CL2013003281A1/es unknown
- 2013-11-19 EC ECSP13013033 patent/ECSP13013033A/es unknown
- 2013-11-20 GT GT201300288A patent/GT201300288A/es unknown
- 2013-11-28 CO CO13279940A patent/CO6811863A2/es active IP Right Grant
- 2013-11-29 CR CR20130629A patent/CR20130629A/es unknown
- 2013-12-06 NI NI201300134A patent/NI201300134A/es unknown
-
2014
- 2014-01-10 MX MX2020013020A patent/MX2020013020A/es unknown
- 2014-03-31 JP JP2014071530A patent/JP5977779B2/ja active Active
- 2014-12-19 US US14/576,721 patent/US9732058B2/en active Active
-
2015
- 2015-06-15 PH PH12015501326A patent/PH12015501326B1/en unknown
- 2015-10-26 IL IL242279A patent/IL242279A/en active IP Right Grant
- 2015-10-26 IL IL242278A patent/IL242278A/en active IP Right Grant
- 2015-10-26 IL IL242285A patent/IL242285A/en active IP Right Grant
- 2015-10-26 IL IL242286A patent/IL242286A/en active IP Right Grant
- 2015-10-26 IL IL242284A patent/IL242284A/en active IP Right Grant
-
2016
- 2016-03-01 CY CY20161100168T patent/CY1117431T1/el unknown
- 2016-03-10 SM SM201600070T patent/SMT201600070B/xx unknown
-
2017
- 2017-07-13 US US15/649,068 patent/US10017493B2/en active Active
- 2017-12-18 HR HRP20171957TT patent/HRP20171957T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100002T patent/CY1120072T1/el unknown
- 2018-05-29 US US15/991,578 patent/US20190092746A1/en not_active Abandoned
-
2019
- 2019-06-19 US US16/445,709 patent/US10858336B2/en active Active
-
2020
- 2020-04-20 HR HRP20200624TT patent/HRP20200624T1/hr unknown
- 2020-05-12 CY CY20201100434T patent/CY1123210T1/el unknown
- 2020-11-12 US US17/096,167 patent/US11524951B2/en active Active
-
2021
- 2021-11-17 CY CY20211100994T patent/CY1125405T1/el unknown
-
2024
- 2024-01-08 US US18/406,693 patent/US20240182441A1/en not_active Abandoned
- 2024-08-28 US US18/818,196 patent/US20240425476A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211682T1 (hr) | 2-(2,4,5-supstituirani-anilino) pirimidinski spojevi | |
| IL228967A0 (en) | Heterocyclic compounds in kinase inhibitors, preparations containing them and their uses | |
| CO7010837A2 (es) | Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf | |
| LT3034497T (lt) | 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamidas | |
| CL2013003790A1 (es) | Composicion de aglutinante para la aglomeracion de minerales finas y procedimiento de granulacion utilizando el mismo | |
| IL245961A0 (en) | Compound (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl] Pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide | |
| SG11201506196SA (en) | Biaryl amide compounds as kinase inhibitors | |
| BRDI7103669S (pt) | "configuração aplicada em carrinho de ferramenta" | |
| SG2014009286A (en) | 3,5-disubstituted alkynylbenzene compound and salt thereof | |
| PT2949722T (pt) | Meio de transferência de calor e armazenamento de calor de sal fundido nanométrico, método de preparação e sua utilização | |
| BR112014003216A2 (pt) | compostos, processos para preparação de compostos de fórmula i, composições agroquímicas, uso de compostos de fórmula i ou viii e uso de pelo menos um composto de fórmula i ou viii | |
| FR2995397B1 (fr) | Intercalaire d'echangeur de chaleur. | |
| ZA201404294B (en) | Substituted 1,2,5-oxadiazole compounds and their use as herbicides | |
| SG10201810057UA (en) | Crystalline fgfr4 inhibitor compound and uses thereof | |
| IL232279A0 (en) | Converted 5,2,1-oxadiazole compounds and their use as herbicides ii | |
| EP2839694A4 (en) | USER MESSAGE MOBILITY INFORMATION TO OPTIMIZE THE SETTINGS OF USER DEVICE PARAMETERS | |
| ZA201404331B (en) | Substituted 1,2,5-oxadiazole compounds and their use as herbicides iii | |
| BR112014031635A2 (pt) | derivados de pró-fármaco de (e)-n-metil-n-( (3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida | |
| EP2708402A4 (en) | HEAT EXCHANGE STRUCTURE FOR VEHICLES | |
| DK4018145T3 (da) | Partikelvarmeveksler med bevægeligt leje | |
| FR2986172B1 (fr) | Tete d'usinage pour centre d'usinage multiaxial | |
| AR092501A1 (es) | Compuestos cristalinos | |
| IL240113B (en) | A method for improving the compositions of nitrate salt using nitric acid used as a thermal transfer agent as a thermal accumulation agent | |
| EP2629935A4 (en) | IMPROVED DRILLING MACHINING TOOL | |
| FR3008784B1 (fr) | Plaque collectrice de collecteur d'un echangeur de chaleur |